ClinicalTrials.gg
CompletedNCT00870467Updated Aug 7, 2012Results posted

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

A Phase 3 interventional study of Double-blind adalimumab and Double-blind Placebo in Rheumatoid Arthritis, sponsored by Abbott. Completed at 88 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
28th of 87
334 · median 160
Started
2009
with 3 others
Phase 3
36 of 87
1 open now
Registered
33rd of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 4 that started in 2009, is one of 36 in phase 3, and was the 33rd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.

Read the detailed description

This was a Phase 3 multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the inhibition of radiographic progression by adalimumab compared with placebo in adult Japanese patients with early rheumatoid arthritis (RA) who had not been previously treated with methotrexate (MTX). Eligible participants were randomized 1:1 to receive either a subcutaneous injection of adalimumab 40 mg or matching placebo every other week (eow) during the 26-week double-blind phase. All participants also received 6 mg to 8 mg MTX weekly as basal treatment for their disease. Participants who experienced an increase in disease activity (more than 20% increase in tender joint count and swollen joint count) at Week 12, 16, or 20 compared with Baseline after having increased MTX dose to 8 mg per week for at least 4 weeks were discontinued from the double-blind phase and were eligible to receive open-label adalimumab 40 mg eow as rescue treatment. Participants who completed the 26 weeks of treatment (either double-blind study drug [adalimumab or placebo] treatment or open-label adalimumab treatment) were eligible to enter the 26-week open-label phase in which they received adalimumab 40 mg eow. Efficacy and safety assessments were performed at Baseline and at designated study visits.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rheumatoid arthritis based on the American College of Rheumatology criteria
  • Methotrexate or leflunomide naïve
  • Disease duration less than or equal to 2 years from diagnosis

Exclusion criteria

Exclusion Criteria

  • History of acute inflammatory joint disease of different origin from rheumatoid arthritis, cancer, lymphoma, leukemia or lymphoproliferative disease, active TB,
  • Previously received anti-TNF therapy anti-IL-6 receptor antibody, CTLA4-Ig, anti-CD20 antibody, cyclophosphamide, cyclosporine, azathioprine, or tacrolimus
  • Joint surgery involving joints to be assessed within 8 weeks prior to Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
334 participants (actual)

Study arms

  • Placebo comparator
    DB Placebo

    Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Drug: Double-blind Placebo

  • Experimental
    DB adalimumab

    Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Biological: Double-blind adalimumab

  • Experimental
    DB Adalimumab/OL Adalimumab

    Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Biological: Double-blind adalimumab · Biological: Open-label Adalimumab

  • Experimental
    DB Placebo/OL Adalimumab

    Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Drug: Double-blind Placebo · Biological: Open-label Adalimumab

  • Experimental
    DB Adalimumab/RE OL Adalimumab

    Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Biological: Double-blind adalimumab · Biological: Open-label Adalimumab · Biological: Open-labelAdalimumabRescue

  • Experimental
    DB Placebo/RE OL Adalimumab

    Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.

    Drug: Double-blind Placebo · Biological: Open-label Adalimumab · Biological: Open-labelAdalimumabRescue

Interventions

  • BiologicalDouble-blind adalimumab

    Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)

    Also known as: ABT-D2E7, adalimumab, Humira

  • DrugDouble-blind Placebo

    Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)

    Also known as: Placebo

  • Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study

    Also known as: ABT-D2E7, adalimumab, Humira

  • Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26

    Also known as: ABT-D2E7, adalimumab, Humira

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Total Sharp X-Ray Score at Week 26

    Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology)

    Patients were ACR20 responders if they had: \>= 20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

    Time frame: Week 26

  2. Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology)

    Patients were ACR50 responders if they had: \>= 50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

    Time frame: Week 26

  3. Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology)

    Patients were ACR70 responders if they had: \>= 70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

    Time frame: Week 26

  4. Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26

    Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.

    Time frame: Baseline, Week 26

  5. Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26

    Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.

    Time frame: Week 26

  6. Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26

    Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of study drug. The number of participants who experienced any adverse event (serious or non-serious) while receiving double-blind study drug is summarized. See the Reported Adverse Event section for details.

    Time frame: Through Week 26

  7. Change From Baseline in Modified Total Sharp X-Ray Score at Week 52

    Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS score (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates diseae progression; small positive/no change indicates slowing/halting of disease progression.

    Time frame: Baseline, Week 52

  8. Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology)

    Patients were ACR20 responders if they had: \>=20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

    Time frame: Week 52

  9. Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology)

    Patients were ACR50 responders if they had: \>=50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

    Time frame: Week 52

  10. Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology)

    Patients were ACR70 responders if they had: \>=70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

    Time frame: Week 52

  11. Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52

    Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.

    Time frame: Baseline, Week 52

  12. Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52

    Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.

    Time frame: Week 52

  13. Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52

    Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of adalimumab. The number of participants who experienced any adverse event (serious or non-serious) while receiving any adalimumab during the study (double-blind adalimumab and/or open-label) is summarized. See the Reported Adverse Event section for details.

    Time frame: Through Week 52

07

Results

Posted Apr 5, 2012

Participant flow

Double-blind
Participant flow — Double-blind
MilestoneDB AdalimumabDB PlaceboDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Started1711630000
Completed1551510000
Not completed16120000
Open-label
Participant flow — Open-label
MilestoneDB AdalimumabDB PlaceboDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Started001451271024
Completed00132120521
Not completed0013753

Outcome measures

PrimaryChange From Baseline in Modified Total Sharp X-Ray Score at Week 26

Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp X-Ray Score at Week 26
units on a scaleDB AdalimumabDB Placebo
Change From Baseline in Modified Total Sharp X-Ray Score at Week 261.5 ± 6.072.4 ± 3.20
Statistical analysis
  • DB Adalimumab vs DB Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryNumber of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology)

Patients were ACR20 responders if they had: \>= 20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology)
participantsDB AdalimumabDB Placebo
Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology)12992
Statistical analysis
  • DB Adalimumab vs DB Placebo · Fisher Exact · p = <0.001
SecondaryNumber of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology)

Patients were ACR50 responders if they had: \>= 50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology)
participantsDB AdalimumabDB Placebo
Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology)11063
Statistical analysis
  • DB Adalimumab vs DB Placebo · Fisher Exact · p = <0.001
SecondaryNumber of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology)

Patients were ACR70 responders if they had: \>= 70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology)
participantsDB AdalimumabDB Placebo
Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology)8137
Statistical analysis
  • DB Adalimumab vs DB Placebo · Fisher Exact · p = <0.001
SecondaryChange From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26

Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26
units on a scaleDB AdalimumabDB Placebo
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26-2.8 ± 1.63-1.8 ± 1.79
Statistical analysis
  • DB Adalimumab vs DB Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryNumber of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26

Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26
participantsDB AdalimumabDB Placebo
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 265224
Statistical analysis
  • DB Adalimumab vs DB Placebo · Fisher Exact · p = <0.001
SecondaryNumber of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26

Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of study drug. The number of participants who experienced any adverse event (serious or non-serious) while receiving double-blind study drug is summarized. See the Reported Adverse Event section for details.

Time frame:
Through Week 26
Reported as:
Number · participants
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26
participantsDB AdalimumabDB Placebo
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26138117
SecondaryChange From Baseline in Modified Total Sharp X-Ray Score at Week 52

Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS score (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates diseae progression; small positive/no change indicates slowing/halting of disease progression.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp X-Ray Score at Week 52
units on a scaleDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Change From Baseline in Modified Total Sharp X-Ray Score at Week 521.6 ± 6.502.1 ± 3.259.6 ± 11.766.8 ± 9.37
SecondaryNumber of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology)

Patients were ACR20 responders if they had: \>=20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology)
participantsDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology)129113421
SecondaryNumber of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology)

Patients were ACR50 responders if they had: \>=50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology)
participantsDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology)117101215
SecondaryNumber of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology)

Patients were ACR70 responders if they had: \>=70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology)
participantsDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology)8785010
SecondaryChange From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52

Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52
units on a scaleDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52-3.7 ± 1.14-3.7 ± 1.58-1.9 ± 1.22-3.4 ± 1.29
SecondaryNumber of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52

Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52
participantsDB Adalimumab/OL AdalimumabDB Placebo/OL AdalimumabDB Adalimumab/RE OL AdalimumabDB Placebo/RE OL Adalimumab
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52625504
SecondaryNumber of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52

Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of adalimumab. The number of participants who experienced any adverse event (serious or non-serious) while receiving any adalimumab during the study (double-blind adalimumab and/or open-label) is summarized. See the Reported Adverse Event section for details.

Time frame:
Through Week 52
Reported as:
Number · participants
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52
participantsAny Adalimumab
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52289

Adverse events

Collected over Through Week 26 for all participants who received at least 1 dose of blinded study drug (adalimumab or placebo) or through Week 52 for participants who received any adalimumab (double-blind and/or open-label, including rescue) in addition to methotrexate.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Adalimumab—7/171 (4.1%)104/171 (60.8%)
DB Placebo—4/163 (2.5%)83/163 (50.9%)
Any Adalimumab—21/326 (6.4%)277/326 (85%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventDB AdalimumabDB PlaceboAny Adalimumab
PneumoniaInfections and infestations1/1710/1634/326
Acute myocardial infarctionCardiac disorders0/1711/1630/326
Pneumocystis jiroveci pneumoniaInfections and infestations0/1711/1630/326
Back painMusculoskeletal and connective tissue disorders0/1711/1630/326
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1711/1630/326
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/1711/1630/326
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/1711/1631/326
CataractEye disorders0/1710/1632/326
GastroenteritisInfections and infestations0/1710/1632/326
Vertigo positionalEar and labyrinth disorders1/1710/1631/326
Most frequent other events
Showing 10 of 43
Most frequent other events
EventDB AdalimumabDB PlaceboAny Adalimumab
NasopharyngitisInfections and infestations26/17127/16397/326
StomatitisGastrointestinal disorders6/17115/16317/326
Injection site reactionGeneral disorders10/1711/16328/326
Alanine aminotransferase increasedInvestigations13/1716/16328/326
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders6/1714/16328/326
Hepatic function abnormalHepatobiliary disorders14/1719/16324/326
RashSkin and subcutaneous tissue disorders10/1715/16326/326
EczemaSkin and subcutaneous tissue disorders6/1716/16324/326
Aspartate aminotransferase increasedInvestigations11/1715/16322/326
DiarrhoeaGastrointestinal disorders5/1711/16318/326

Baseline characteristics

Age Continuous
Age Continuous(years)DB AdalimumabDB PlaceboTotal
Mean54.0 ± 13.1354.0 ± 13.2054.0 ± 13.15
Sex: Female, Male
Sex: Female, Male(Participants)DB AdalimumabDB PlaceboTotal
Female144128272
Male273562
Region of Enrollment
Region of Enrollment(participants)DB AdalimumabDB PlaceboTotal
Japan171163334
08

Study locations

88 sites
  • Site Reference ID/Investigator# 46861
    Anjo, Japan
  • Site Reference ID/Investigator# 46919
    Aomori, Japan
  • Site Reference ID/Investigator# 46805
    Chiba, Japan
  • Site Reference ID/Investigator# 46806
    Chiba, Japan
  • Site Reference ID/Investigator# 46880
    Chiba, Japan
  • Site Reference ID/Investigator# 46881
    Chiba, Japan
  • Site Reference ID/Investigator# 46890
    Fuchu, Japan
  • Site Reference ID/Investigator# 46902
    Fukuoka, Japan
  • Site Reference ID/Investigator# 46903
    Fukuoka, Japan
  • Site Reference ID/Investigator# 46904
    Fukuoka, Japan
  • Site Reference ID/Investigator# 46856
    Gifu, Japan
  • Site Reference ID/Investigator# 46944
    Gunma, Japan
  • Site Reference ID/Investigator# 46893
    Hiroshima, Japan
  • Site Reference ID/Investigator# 46894
    Hiroshima, Japan
  • Site Reference ID/Investigator# 12161
    Hokkaido, Japan
  • Site Reference ID/Investigator# 46916
    Hokkaido, Japan
  • Site Reference ID/Investigator# 46918
    Hokkaido, Japan
  • Site Reference ID/Investigator# 46865
    Hyogo, Japan
  • Site Reference ID/Investigator# 46871
    Hyogo, Japan
  • Site Reference ID/Investigator# 46801
    Ibaraki, Japan
  • Site Reference ID/Investigator# 46925
    Ibaraki, Japan
  • Site Reference ID/Investigator# 46800
    Iwate, Japan
  • Site Reference ID/Investigator# 46873
    Kagoshima, Japan
  • Site Reference ID/Investigator# 46874
    Kagoshima, Japan
  • Site Reference ID/Investigator# 46845
    Kanagawa, Japan
  • Site Reference ID/Investigator# 46899
    Kanagawa, Japan
  • Site Reference ID/Investigator# 46901
    Kanagawa, Japan
  • Site Reference ID/Investigator# 46851
    Kanazawa, Japan
  • Site Reference ID/Investigator# 46852
    Kanazawa, Japan
  • Site Reference ID/Investigator# 46802
    Kawagoe, Japan
  • Site Reference ID/Investigator# 46900
    Kawasaki, Japan
  • Site Reference ID/Investigator# 46875
    Kirishima, Japan
  • Site Reference ID/Investigator# 46870
    Kitakyushu, Japan
  • Site Reference ID/Investigator# 46872
    Kumamoto, Japan
  • Site Reference ID/Investigator# 46912
    Kumamoto, Japan
  • Site Reference ID/Investigator# 46864
    Kyoto, Japan
  • Site Reference ID/Investigator# 46943
    Maebashi, Japan
  • Site Reference ID/Investigator# 46898
    Matsuyama, Japan
  • Site Reference ID/Investigator# 46915
    Miyazaki, Japan
  • Site Reference ID/Investigator# 46853
    Nagano, Japan
  • Site Reference ID/Investigator# 46855
    Nagano, Japan
  • Site Reference ID/Investigator# 46909
    Nagasaki, Japan
  • Site Reference ID/Investigator# 46910
    Nagasaki, Japan
  • Site Reference ID/Investigator# 46911
    Nagasaki, Japan
  • Site Reference ID/Investigator# 46858
    Nagoya, Japan
  • Site Reference ID/Investigator# 46860
    Nagoya, Japan
  • Site Reference ID/Investigator# 46877
    Nara, Japan
  • Site Reference ID/Investigator# 46885
    Nara, Japan
  • Site Reference ID/Investigator# 46848
    Niigata, Japan
  • Site Reference ID/Investigator# 46906
    Niigata, Japan
  • Site Reference ID/Investigator# 46914
    Oita, Japan
  • Site Reference ID/Investigator# 46869
    Okayama, Japan
  • Site Reference ID/Investigator# 46886
    Okayama, Japan
  • Site Reference ID/Investigator# 46887
    Okayama, Japan
  • Site Reference ID/Investigator# 46892
    Okayama, Japan
  • Site Reference ID/Investigator# 46876
    Okinawa, Japan
  • Site Reference ID/Investigator# 46946
    Osaka, Japan
  • Site Reference ID/Investigator# 46947
    Osaka, Japan
  • Site Reference ID/Investigator# 46842
    Rifu, Japan
  • Site Reference ID/Investigator# 46846
    Sagamihara, Japan
  • Site Reference ID/Investigator# 46803
    Saitama, Japan
  • Site Reference ID/Investigator# 46804
    Saitama, Japan
  • Site Reference ID/Investigator# 46878
    Saitama, Japan
  • Site Reference ID/Investigator# 46879
    Saitama, Japan
  • Site Reference ID/Investigator# 46917
    Sapporo, Japan
  • Site Reference ID/Investigator# 46942
    Shimotsuke, Japan
  • Site Reference ID/Investigator# 46854
    Shizuoka, Japan
  • Site Reference ID/Investigator# 46857
    Shizuoka, Japan
  • Site Reference ID/Investigator# 46859
    Shizuoka, Japan
  • Site Reference ID/Investigator# 46895
    Takamatsu, Japan
  • Site Reference ID/Investigator# 46843
    Tokyo, Japan
  • Site Reference ID/Investigator# 46844
    Tokyo, Japan
  • Site Reference ID/Investigator# 46850
    Tokyo, Japan
  • Site Reference ID/Investigator# 46882
    Tokyo, Japan
  • Site Reference ID/Investigator# 46883
    Tokyo, Japan
  • Site Reference ID/Investigator# 46884
    Tokyo, Japan
  • Site Reference ID/Investigator# 46888
    Tokyo, Japan
  • Site Reference ID/Investigator# 46889
    Tokyo, Japan
  • Site Reference ID/Investigator# 46891
    Tokyo, Japan
  • Site Reference ID/Investigator# 46896
    Tokyo, Japan
  • Site Reference ID/Investigator# 46849
    Toyama, Japan
  • Site Reference ID/Investigator# 46907
    Toyama, Japan
  • Site Reference ID/Investigator# 46862
    Toyoake, Japan
  • Site Reference ID/Investigator# 46866
    Toyohashi, Japan
  • Site Reference ID/Investigator# 46926
    Tsukuba, Japan
  • Site Reference ID/Investigator# 46863
    Tsu, Japan
  • Site Reference ID/Investigator# 46897
    Yokohama, Japan
  • Site Reference ID/Investigator# 46905
    Yokohama, Japan
09

References and documents

Publications

  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014 May;53(5):904-13. doi: 10.1093/rheumatology/ket465. Epub 2014 Jan 17. PubMed 24441150 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2009
First posted
Mar 27, 2009
Start
Mar 2009
Primary completionActual
Mar 2011
CompletionActual
Aug 2011
Results first posted
Apr 5, 2012
Last update
Aug 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00870467
Lead sponsor
Abbott
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2009
Start date
Mar 2009
Primary completion
Mar 2011
Completion
Aug 2011
Results posted
Apr 5, 2012
Last update
Aug 7, 2012

Study contacts

Hiroshi Ukai, BS
study director · Abbott Japan Co.,Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion